FDA approves Biotronik ICD systems for use with MRI scans

The FDA approved the ProMRI implantable cardioverter defibrillator (ICD) systems for use with full-body MRI scans on Dec. 22.

The approval includes the Iperia DR-T in the DF-1 and DF-4 configurations, the Iperia DX System and the Inventra ProMRI DX, according to a news release from Biotronik, the devices’ manufacturer. The company cited research that found 75 percent of patients with an ICD or pacemaker will need an MRI scan during their lives.

Biotronik said this is the third FDA approval in the past 18 months for its ProMRI technology, which allows patients with approved pacemakers, implantable defibrillators or cardiac monitors to have 1.5 Tesla MRI scans without an exclusion zone.

“Our goal is to integrate ProMRI technology across our entire line of implantable systems, and in doing so, provide access to MRI diagnostic scans for all [cardiac rhythm management] patients,” Biotronik President Marlou Janssen said in a news release.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.